Stocks Overview

LAST PRICE
28.8300
TODAY'S CHANGE (%)
Trending Up0.6300 (2.2340%)

Bid / Lots
28.3000/ 1
Ask / Lots
29.4500/ 1
Open / Previous Close
28.4400 / 28.2000
Day Range
Low 28.3600
High 28.8900
52 Week Range
Low 26.3200
High 42.7200
Volume
484,333
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 28.2
Time	Volume	GMAB
09:32 ET	4378	28.43
09:34 ET	3159	28.39
09:36 ET	7869	28.44
09:38 ET	2542	28.4
09:39 ET	400	28.4
09:41 ET	350	28.43
09:43 ET	301	28.44
09:45 ET	800	28.44
09:48 ET	5161	28.48
09:50 ET	300	28.49
09:52 ET	1120	28.49
09:54 ET	925	28.47
09:56 ET	4137	28.43
09:57 ET	4071	28.43
09:59 ET	1100	28.45
10:01 ET	2222	28.52
10:03 ET	968	28.6
10:06 ET	1150	28.62
10:08 ET	340	28.61
10:10 ET	400	28.58
10:12 ET	1295	28.57
10:14 ET	1399	28.58
10:15 ET	2309	28.63
10:17 ET	2340	28.74
10:19 ET	880	28.68
10:21 ET	1900	28.61
10:24 ET	3286	28.63
10:26 ET	2218	28.63
10:28 ET	1685	28.61
10:30 ET	1833	28.63
10:32 ET	200	28.64
10:33 ET	826	28.62
10:35 ET	150	28.61
10:37 ET	4062	28.57
10:39 ET	2934	28.59
10:42 ET	400	28.55
10:44 ET	2569	28.5393
10:46 ET	300	28.54
10:48 ET	2188	28.52
10:50 ET	1711	28.52
10:51 ET	1068	28.56
10:53 ET	526	28.56
10:55 ET	300	28.525
10:57 ET	2917	28.5
11:00 ET	1000	28.495
11:02 ET	1032	28.54
11:04 ET	218	28.56
11:06 ET	1184	28.62
11:08 ET	900	28.66
11:09 ET	1200	28.69
11:11 ET	600	28.69
11:13 ET	200	28.68
11:20 ET	10125	28.74
11:22 ET	600	28.75
11:24 ET	200	28.75
11:26 ET	1200	28.76
11:27 ET	1069	28.77
11:29 ET	999	28.78
11:31 ET	518	28.74
11:33 ET	420	28.77
11:36 ET	300	28.77
11:38 ET	600	28.79
11:40 ET	800	28.78
11:44 ET	1798	28.78
11:45 ET	3900	28.78
11:47 ET	1423	28.77
11:49 ET	1200	28.77
11:51 ET	200	28.75
11:54 ET	536	28.73
11:56 ET	500	28.73
12:00 ET	620	28.7
12:02 ET	312	28.7
12:03 ET	1902	28.6965
12:05 ET	1529	28.7
12:07 ET	1000	28.66
12:09 ET	120	28.6791
12:12 ET	150	28.69
12:14 ET	5370	28.63
12:16 ET	400	28.64
12:18 ET	100	28.63
12:20 ET	200	28.63
12:21 ET	1100	28.65
12:23 ET	918	28.68
12:25 ET	100	28.675
12:27 ET	200	28.675
12:30 ET	1200	28.63
12:32 ET	5001	28.6204
12:34 ET	1129	28.62
12:36 ET	500	28.6
12:38 ET	720	28.6
12:41 ET	280	28.62
12:43 ET	400	28.63
12:48 ET	400	28.615
12:50 ET	35947	28.67
12:52 ET	700	28.65
12:54 ET	400	28.635
12:56 ET	6188	28.71
12:57 ET	200	28.71
01:01 ET	300	28.67
01:03 ET	725	28.68
01:06 ET	506	28.67
01:08 ET	100	28.7
01:12 ET	9067	28.6664
01:14 ET	1703	28.645
01:15 ET	1482	28.665
01:17 ET	100	28.68
01:19 ET	100	28.69
01:21 ET	417	28.71
01:26 ET	4788	28.74
01:28 ET	400	28.745
01:30 ET	412	28.71
01:32 ET	100	28.715
01:33 ET	580	28.725
01:35 ET	200	28.72
01:37 ET	100	28.74
01:44 ET	100	28.74
01:46 ET	1000	28.74
01:48 ET	100	28.745
01:51 ET	200	28.73
01:53 ET	845	28.71
01:55 ET	735	28.72
01:57 ET	128	28.7237
02:02 ET	814	28.7193
02:04 ET	100	28.705
02:06 ET	1500	28.75
02:08 ET	900	28.75
02:11 ET	100	28.74
02:13 ET	478	28.7288
02:15 ET	880	28.73
02:18 ET	230	28.727
02:20 ET	804	28.74
02:22 ET	2406	28.77
02:24 ET	5607	28.76
02:26 ET	200	28.755
02:27 ET	1164	28.77
02:29 ET	900	28.77
02:31 ET	519	28.78
02:33 ET	8366	28.79
02:36 ET	2356	28.78
02:38 ET	1127	28.8
02:40 ET	1027	28.795
02:42 ET	610	28.79
02:44 ET	700	28.79
02:45 ET	1002	28.8399
02:47 ET	11839	28.83
02:49 ET	660	28.8399
02:51 ET	1678	28.81
02:54 ET	519	28.8444
03:00 ET	503	28.83
03:03 ET	300	28.84
03:05 ET	429	28.83
03:07 ET	2123	28.83
03:09 ET	3056	28.855
03:12 ET	4091	28.88
03:14 ET	1275	28.86
03:16 ET	600	28.87
03:18 ET	805	28.86
03:20 ET	429	28.83
03:21 ET	1348	28.88
03:23 ET	3749	28.8883
03:25 ET	3240	28.86
03:27 ET	500	28.88
03:30 ET	917	28.83
03:32 ET	1256	28.835
03:34 ET	1711	28.86
03:36 ET	1700	28.84
03:38 ET	301	28.825
03:39 ET	650	28.8
03:41 ET	4919	28.8
03:43 ET	3873	28.83
03:45 ET	4008	28.82
03:48 ET	3421	28.84
03:50 ET	8040	28.85
03:52 ET	5898	28.825
03:54 ET	7364	28.84
03:56 ET	8761	28.855
03:57 ET	5576	28.855
03:59 ET	13582	28.83

Data delayed at least 15 minutes.

Today
- DJ Genmab A/S Stock Rises Monday, Outperforms Market, from 5 hours ago by Dow Jones
  5 hours ago by Dow Jones
- Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
- DJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
Yesterday
- Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody(R) CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
Jun 1, 2024
- Investigational Acasunlimab (DuoBody(R) -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC), from 10:00AM ET on Saturday Jun 01, 2024 by Dow Jones
  10:00AM ET on Saturday Jun 01, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesGMAB Genmab A/S	18.6B	23.9x	+22.71%
United StatesDNLI Denali Therapeutics Inc	2.6B	-21.1x	---
United StatesFOLD Amicus Therapeutics Inc	2.9B	-20.3x	---
United StatesMOR MorphoSys AG	2.8B	-5.6x	---
United StatesGLPG Galapagos NV	1.8B	54.8x	---
United StatesARWR Arrowhead Pharmaceuticals Inc	2.9B	-5.8x	---
As of 2024-06-03

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact Information

Headquarters: Kalvebod Brygge 43KOEBENHAVN V, Denmark 1560
Phone: ---
Fax: ---

Executives

Independent Chairman of the Board: Deirdre Connelly
President, Chief Executive Officer: Jan Van De Winkel
Independent Deputy Chairman of the Board: Pernille Erenbjerg
Chief Financial Officer, Executive Vice President: Anthony Pagano
Chief Operating Officer, Executive Vice President: Anthony Mancini

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$18.6B
Revenue (TTM)	$2.6B
Shares Outstanding	661.3M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.98
EPS	$1.20
Book Value	$7.04
P/E Ratio	23.9x
Price/Sales (TTM)	7.2
Price/Cash Flow (TTM)	---
Operating Margin	32.00%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Genmab A/S
NASDAQ:GMABUnited States

Search Criteria

Charts

Recent News

Today

DJ Genmab A/S Stock Rises Monday, Outperforms Market, from 5 hours ago by Dow Jones

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), from 8 hours ago by Dow Jones

DJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 10 hours ago by Dow Jones

Yesterday

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody(R) CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma, from 23 hours ago by Dow Jones

Jun 1, 2024

Investigational Acasunlimab (DuoBody(R) -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC), from 10:00AM ET on Saturday Jun 01, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar